People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inhibrx, Inc. | — | Biotechnology | Growth/Late | $668.6M | $3.3B | 2023 |
| Forian Inc. | — | Other Technology | Series B | $24.0M | $485.0M | 2021 |
Kristiina Vuori at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kristiina Vuori on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Judith Li | 1 | 8 |
| Scott Ogur | 1 | 3 |
| Jon Faiz Kayyem | 1 | 2 |
| Jon Kayyem | 1 | 2 |
| Doug Forsyth | 1 | 2 |
| Max Wygod | 1 | 2 |
| Daniel Barton | 1 | 2 |
| Shahir Kassam-Adams | 1 | 2 |
| Edward Spaniel | 1 | 1 |
| Kelly Faiz Deck | 1 | 1 |
| Judith Faiz Li | 1 | 1 |
| Doug Faiz Forsyth | 1 | 1 |
| Margery Faiz Fischbein | 1 | 1 |
| Mark Lappe | 1 | 1 |
| Michael Vesey | 1 | 1 |
| Jennifer Hajj | 1 | 1 |
| Adam Dublin | 1 | 1 |
| Ian Banwell | 1 | 1 |
| Mark Adler | 1 | 1 |
| Stanley Trotman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.